Buzaid A C, Todd M B
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510.
Semin Oncol. 1989 Feb;16(1 Suppl 1):12-9.
The management of renal cell carcinoma remains a therapeutic challenge. For patients with localized disease, surgery represents the only curative treatment modality. Neither postoperative radiotherapy nor systemic hormonal therapy is of additional benefit in this setting. There are ongoing studies evaluating the role of biologic response modifiers, such as interferon and interleukin-2, as adjuncts to surgery. Patients with recurrent or metastatic disease have a poor prognosis and are a natural target for clinical trials designed to evaluate potential therapeutic modalities. Cytotoxic drugs and hormonal therapies are usually ineffective. The advent of interferon, and more recently of interleukin-2, has resulted in a modest advance in therapy of metastatic renal cell carcinoma. Studies designed to evaluate mechanisms associated with intrinsic or acquired resistance to cytotoxic drugs, as well as to biologic response modifiers, will lead to a better understanding of the biology of the disease and, ultimately, to a more rational and effective use of various therapeutic agents.
肾细胞癌的治疗仍然是一项治疗挑战。对于局限性疾病患者，手术是唯一的治愈性治疗方式。在此情况下，术后放疗和全身激素治疗均无额外益处。目前正在进行研究，评估生物反应调节剂（如干扰素和白细胞介素-2）作为手术辅助手段的作用。复发或转移性疾病患者预后较差，是旨在评估潜在治疗方式的临床试验的天然研究对象。细胞毒性药物和激素治疗通常无效。干扰素的出现，以及最近白细胞介素-2的出现，使转移性肾细胞癌的治疗取得了一定进展。旨在评估与对细胞毒性药物以及生物反应调节剂的内在或获得性耐药相关机制的研究，将有助于更好地理解该疾病的生物学特性，并最终更合理有效地使用各种治疗药物。
